Press Releases hVIVO plc

Equities

Delayed London S.E. Other stock markets 15:25:01 27/06/2024 BST			5-day change	1st Jan Change
27.1 ^GBX	+0.37%		0.00%	+14.11%

06-03	HVIVO says Omicron contract validates move to Canary Wharf facility	AN
06-03	HVIVO plc Signs £2.5 Million Contract with A Mid-Sized Pharmaceutical Company to Initiate an Omicron characterization study	CI

HVIVO : Interim Results 2023	12/09/23	PU
HVIVO : Trading Update H1 2023	26/07/23	PU
HVIVO : 2023 AGM Notice & Proxy Form	28/04/23	PU
HVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal	14/11/22	EQ
Open Orphan : Interim Results Presentation September 2022	09/09/22	PU
Open Orphan : 2022 AGM Form of Proxy	10/06/22	PU
Open Orphan : 2022 AGM Notice	10/06/22	PU
Open Orphan : Annual Report 2021	08/06/22	PU
Open Orphan : Investors Presentation June 2022	08/06/22	PU
AIM ImmunoTech : Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy	12/07/21	AQ
AIM ImmunoTech : Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy	09/07/21	AQ
Open Orphan : Publication of positive results in journal ● ●	16/03/20	PU
Open Orphan : Publication of positive results in journal	16/03/20	PU
Open Orphan : Holding(s) in Company ●	12/03/20	PU
Open Orphan : Publication of Positive Results in Journal ●	10/03/20	PU
Open Orphan : Completion of Compulsory Acquisition of Shares ● ●	09/03/20	PU
Open Orphan : Completion of Compulsory Acquisition of Shares	09/03/20	PU
Open Orphan : Coronavirus Challenge Study Model	09/03/20	PU
Open Orphan : New Contract ● ●	06/03/20	PU
Open Orphan : New Contract	06/03/20	PU

No results for this search